Cargando…

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Detalles Bibliográficos
Autores principales:	Hsieh, Emily M., Myers, Regina M., Yates, Bonnie, Annesley, Colleen, John, Samuel, Taraseviciute, Agne, Steinberg, Seth M., Sheppard, Jennifer, Chung, Perry, Chen, Lee, Lee, Daniel W., DiNofia, Amanda, Grupp, Stephan A., Verneris, Michael R., Laetsch, Theodore W., Bhojwani, Deepa, Brown, Patrick A., Pulsipher, Michael A., Rheingold, Susan R., Gardner, Rebecca A., Gore, Lia, Shah, Nirali N., Lamble, Adam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631644/ https://www.ncbi.nlm.nih.gov/pubmed/35834728 http://dx.doi.org/10.1182/bloodadvances.2022008093

Ejemplares similares

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
por: Myers, Regina M., et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL
por: DiNofia, Amanda M., et al.
Publicado: (2019)

Hypogammaglobulinemia due to CAR T-cell therapy
por: Doan, Andrew, et al.
Publicado: (2017)

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States
por: DiNofia, Amanda M., et al.
Publicado: (2016)

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
por: Schuelke, Matthew R., et al.
Publicado: (2023)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
por: Stein, Andrew M., et al.
Publicado: (2019)

Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy
por: Lee, Brittany M., et al.
Publicado: (2023)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
por: Faruqi, Aiman J., et al.
Publicado: (2022)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Roadblocks to success for RNA CARs in solid tumors
por: Singh, Nathan, et al.
Publicado: (2015)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase III high‐risk B acute lymphoblastic leukemia trial AALL0232
por: DiNofia, Amanda M., et al.
Publicado: (2017)

Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia
por: Stokke, Jamie L., et al.
Publicado: (2021)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities
por: Rocco, Joseph M., et al.
Publicado: (2023)

How I treat refractory CRS and ICANS after CAR T-cell therapy
por: Jain, Michael D., et al.
Publicado: (2023)

Therapeutic manipulation of innate lymphoid cells
por: Cobb, Laura M., et al.
Publicado: (2021)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
por: Lamble, Adam, et al.
Publicado: (2017)

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
por: Hucks, George, et al.
Publicado: (2019)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
por: Chen, Gregory M., et al.
Publicado: (2023)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433
por: Lew, Glen, et al.
Publicado: (2020)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
por: Koo, Jane, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jbrs7t1f2tbe3ln5u8ll0tg9k5